The results of the current studies to determine the optimal strategy for metastatic gastric cancer remain contrversial worldwide.
Hypothesis: Cytoreductive Gastrectomy After Systemic Therapy will improve survival time for metastasis gastric cancer compared to Systemic Therapy alone.
Age 18-75
GCLM detected on surgical exploration and demonstrated by histology or cytology
Localized peritoneal carcinomatosis (P1 or P2 score), according to the classification of the Japanese Research Society for Gastric Cancer
Liver metastasis lesions of maximum diameter ≤5 cm
Any extra-abdominal metastasis at diagnosis or during systemic treatment.
Past history of malignancy other than gastric cancer diagnosed in the last 5 years except for basal cell carcinoma of skin or preinvasive cancer of cervix
Patients in the reproductive age who declined to use an adequate means of contraception
Significant disease or conditions which, in the investigator's opinion, would exclude patient from the study